Lonza Group AG
LONN
Rangering i aksjer
#447
Lonza Group AG, together with its subsidiaries, operates as a contract... Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Aksjekurs
$766.95
Markedsverdi
$53.57B
Endring (1 dag)
1.35%
Endring (1 år)
9.01%
Land
CH
Handel Lonza Group AG (LONN)
Kategori
Healthcare
Antall utestående aksjer for Lonza Group AG (LONN)
Antall utestående aksjer per October 2026: 0
Ifølge Lonza Group AG sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av October 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Lonza Group AG (LONN) fra 2004 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2025 | 70.02M | -1.68% |
| 2024 | 71.22M | -3.30% |
| 2023 | 73.65M | -0.78% |
| 2022 | 74.23M | -0.04% |
| 2021 | 74.26M | -0.20% |
| 2020 | 74.40M | 0.40% |
| 2019 | 74.11M | -0.40% |
| 2018 | 74.41M | 9.62% |
| 2017 | 67.88M | 28.40% |
| 2016 | 52.87M | 0.39% |
| 2015 | 52.66M | 0.91% |
| 2014 | 52.19M | 0.18% |
| 2013 | 52.10M | -6.80% |
| 2012 | 55.90M | 0.28% |
| 2011 | 55.74M | -1.48% |
| 2010 | 56.58M | 3.22% |
| 2009 | 54.81M | -3.69% |
| 2008 | 56.91M | -0.10% |
| 2007 | 56.97M | -3.42% |
| 2006 | 58.99M | 15.34% |
| 2005 | 51.15M | -0.01% |
| 2004 | 51.15M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| 0.00 | - |
BE
|
